JP2015516418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516418A5 JP2015516418A5 JP2015511510A JP2015511510A JP2015516418A5 JP 2015516418 A5 JP2015516418 A5 JP 2015516418A5 JP 2015511510 A JP2015511510 A JP 2015511510A JP 2015511510 A JP2015511510 A JP 2015511510A JP 2015516418 A5 JP2015516418 A5 JP 2015516418A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- range
- formula
- active pharmaceutical
- pharmaceutical ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261643454P | 2012-05-07 | 2012-05-07 | |
| US61/643,454 | 2012-05-07 | ||
| PCT/US2013/038770 WO2013169520A1 (en) | 2012-05-07 | 2013-04-30 | Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015516418A JP2015516418A (ja) | 2015-06-11 |
| JP2015516418A5 true JP2015516418A5 (enExample) | 2016-05-26 |
| JP6276756B2 JP6276756B2 (ja) | 2018-02-07 |
Family
ID=48428670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015511510A Expired - Fee Related JP6276756B2 (ja) | 2012-05-07 | 2013-04-30 | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤 |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104363898A (zh) * | 2012-05-07 | 2015-02-18 | 百时美施贵宝爱尔兰控股公司 | [(1s)-1-{[(2s,4r)-4-(7-氯-4-甲氧基异喹啉-1-基氧基)-2-({(1r,2s)-1-[(环丙基磺酰基)氨甲酰基]-2-乙烯基环丙基}氨甲酰基)吡咯烷-1-基]羰基}-2,2-二甲基丙基]氨基甲酸1,1-二甲基乙基酯的口服固体给药制剂 |
| MX360452B (es) | 2012-10-19 | 2018-11-01 | Bristol Myers Squibb Co | Inhibidores del virus de la hepatitis c. |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃ型肝炎ウイルス阻害剤 |
| WO2019130341A1 (en) * | 2017-12-26 | 2019-07-04 | Hetero Labs Limited | Capsule compositions comprising lopinavir and ritonavir |
| EA202092131A1 (ru) | 2018-03-14 | 2020-11-27 | Кэнди Терапьютикс Лимитед | Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9710071B (en) * | 1996-11-21 | 1998-05-25 | Abbott Lab | Pharmaceutical composition. |
| NZ526169A (en) * | 2000-10-31 | 2005-12-23 | Boehringer Ingelheim Pharma | Oral dosage self-emulsifying formulations of pyranone protease inhibitors |
| US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| ES2435799T3 (es) * | 2008-10-09 | 2013-12-23 | Anadys Pharmaceuticals, Inc. | Un método de inhibición del virus de la hepatitis C mediante combinación de una 5,6-dihidro-1H-piridin-2-ona y de uno o más compuestos antivirales adicionales |
| US8252821B2 (en) * | 2009-04-14 | 2012-08-28 | Bristol-Myers Squibb Company | Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound |
-
2013
- 2013-04-29 US US13/872,652 patent/US20130302414A1/en not_active Abandoned
- 2013-04-30 PT PT13722217T patent/PT2846780T/pt unknown
- 2013-04-30 HR HRP20181583TT patent/HRP20181583T1/hr unknown
- 2013-04-30 RS RS20181141A patent/RS57881B1/sr unknown
- 2013-04-30 MY MYPI2014703294A patent/MY171378A/en unknown
- 2013-04-30 LT LTEP13722217.0T patent/LT2846780T/lt unknown
- 2013-04-30 ES ES13722217.0T patent/ES2688817T3/es active Active
- 2013-04-30 SM SM20180506T patent/SMT201800506T1/it unknown
- 2013-04-30 EA EA201492039A patent/EA028749B1/ru not_active IP Right Cessation
- 2013-04-30 KR KR20147033971A patent/KR20150004921A/ko not_active Ceased
- 2013-04-30 SI SI201331126T patent/SI2846780T1/sl unknown
- 2013-04-30 SG SG11201406964QA patent/SG11201406964QA/en unknown
- 2013-04-30 PE PE2014001988A patent/PE20142439A1/es not_active Application Discontinuation
- 2013-04-30 AU AU2013260005A patent/AU2013260005B2/en not_active Ceased
- 2013-04-30 CN CN201380023724.1A patent/CN104363899A/zh active Pending
- 2013-04-30 EP EP13722217.0A patent/EP2846780B1/en active Active
- 2013-04-30 NZ NZ630248A patent/NZ630248A/en not_active IP Right Cessation
- 2013-04-30 WO PCT/US2013/038770 patent/WO2013169520A1/en not_active Ceased
- 2013-04-30 PL PL13722217T patent/PL2846780T3/pl unknown
- 2013-04-30 CA CA2872765A patent/CA2872765A1/en not_active Abandoned
- 2013-04-30 BR BR112014027676A patent/BR112014027676A2/pt not_active IP Right Cessation
- 2013-04-30 JP JP2015511510A patent/JP6276756B2/ja not_active Expired - Fee Related
- 2013-04-30 MX MX2014013220A patent/MX358545B/es active IP Right Grant
- 2013-04-30 DK DK13722217.0T patent/DK2846780T3/en active
- 2013-05-06 UY UY0001034785A patent/UY34785A/es unknown
- 2013-05-06 AR ARP130101544A patent/AR090954A1/es unknown
- 2013-05-06 TW TW102116102A patent/TWI577392B/zh not_active IP Right Cessation
-
2014
- 2014-10-27 PH PH12014502405A patent/PH12014502405A1/en unknown
- 2014-11-03 IL IL235466A patent/IL235466B/en active IP Right Grant
- 2014-11-06 CL CL2014003012A patent/CL2014003012A1/es unknown
- 2014-12-02 CO CO14265249A patent/CO7141457A2/es unknown
- 2014-12-05 ZA ZA2014/08967A patent/ZA201408967B/en unknown
-
2018
- 2018-10-15 CY CY181101051T patent/CY1120756T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516418A5 (enExample) | ||
| RU2709612C2 (ru) | САМОЭМУЛЬГИРУЮЩАЯСЯ КОМПОЗИЦИЯ ω3 ЖИРНОЙ КИСЛОТЫ | |
| EP3023099B1 (en) | Self-emulsifying composition of -3 fatty acid | |
| RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
| JP6276756B2 (ja) | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤 | |
| CO6311066A2 (es) | Composiciones de alta densidad que contienen posaconazol y formulaciones que comprenden las mismas | |
| JP2015038155A5 (enExample) | ||
| ES2948444T3 (es) | Composiciones que comprenden 15-HEPE | |
| TWI654981B (zh) | 包含度他雄胺和丙二醇單月桂酸酯的醫藥組成物及其製備方法 | |
| RU2015115127A (ru) | Жидкие лекарственные композиции апиксабана | |
| BRPI0808945A2 (pt) | Composição | |
| JP2015504924A5 (enExample) | ||
| JP2016503030A5 (enExample) | ||
| RU2016119746A (ru) | Стабильный состав инсулина глулизин | |
| AR103653A1 (es) | Complejos de acetato de abiraterona, proceso para prepararlos y composiciones farmacéuticas que los contienen | |
| JP2015523361A5 (ja) | 低分子薬の非経口注射用の安定な製剤 | |
| JP2025061087A (ja) | １５－オキソ－ｅｐａまたは１５－オキソ－ｄｇｌａを含む組成物、ならびにその作製及び使用方法 | |
| AU2015270187A1 (en) | Oral pharmaceutical composition of isotretinoin | |
| CA2690490A1 (en) | Pharmaceutical formulations of loratadine for encapsulation and combinations thereof | |
| JP5750278B2 (ja) | カンデサルタンシレキセチルのカプセル充填用組成物 | |
| JP6082503B1 (ja) | ソフトカプセル剤 | |
| JP2006522011A (ja) | 安定なカルプロフェン組成物 | |
| JP2021504479A5 (enExample) | ||
| JP2016514706A5 (enExample) | ||
| US20170326161A1 (en) | Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof |